Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937882 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
A Phase 3 study, sponsored by ReGenTree.
- Completed
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
NCT03937882 is a Phase 3 study that has completed, run by ReGenTree. The registered enrollment target is 700 participants.
The verdict
NCT03937882, a Phase 3 study, has completed, sponsored by ReGenTree.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Interventions
- DRUG Placebo
- DRUG RGN-259
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2021-10-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03937882
The ClinicalTrials.gov registry entry for NCT03937882 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReGenTree, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03937882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03937882 about?
NCT03937882 is a clinical study titled "Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3". The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT03937882?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2019-05-24. Estimated completion is 2021-10-07.
What interventions are being tested in trial NCT03937882?
The interventions under investigation include: Placebo (DRUG), RGN-259 (DRUG).
Who is sponsoring clinical trial NCT03937882?
This trial is sponsored by ReGenTree, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.